S-Adenosylmethionine/Silybin

Verify with FDA CVM →

16 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
16
Total Reports
2
Deaths Reported
1250.0%
Death Rate

Active Ingredients

S-Adenosylmethionine/Silybin

Administration Routes

OralUnknown

Species Affected

Dog 14
Cat 2

Most Affected Breeds

Dachshund (unspecified) 2
Schnauzer - Miniature 2
Crossbred Canine/dog 1
Schnauzer (unspecified) 1
Retriever - Labrador 1
Terrier - West Highland White 1
Chihuahua 1
Maltese 1
Deutsche Dogge, Great Dane 1
Beagle 1

Most Reported Reactions

Other abnormal test result NOS 6
Elevated alanine aminotransferase (ALT) 3
Death by euthanasia 2
Lack of efficacy - NOS 2
Neoplasia NOS 2
Elevated serum alkaline phosphatase (SAP) 2
Acute renal failure 1
Not eating 1
Swelling NOS 1
Localised oedema (not application site) 1
Elevated creatinine 1
Elevated blood urea nitrogen (BUN) 1

Outcome Breakdown

Ongoing
6 (37.5%)
Outcome Unknown
4 (25.0%)
Recovered/Normal
3 (18.8%)
Euthanized
2 (12.5%)
Recovered with Sequela
1 (6.3%)

Data Summary

Metric Value
Total adverse event reports 16
Reports involving death 2
Case-fatality rate (reported events) 1250.0%
Distinct species in reports 2
Distinct breeds in reports 14
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

S-Adenosylmethionine/Silybin Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 16 adverse event reports referencing S-Adenosylmethionine/Silybin, including 2 reports in which the animal died — a 1250.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: S-Adenosylmethionine/Silybin. Reported administration routes include Oral, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in S-Adenosylmethionine/Silybin reports are Dog (14 reports), Cat (2 reports), with Dog accounting for the largest share. Within those species, Dachshund (unspecified) (2), Schnauzer - Miniature (2), Crossbred Canine/dog (1) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with S-Adenosylmethionine/Silybin are Other abnormal test result NOS (6), Elevated alanine aminotransferase (ALT) (3), Death by euthanasia (2), Lack of efficacy - NOS (2). Of the 16 reports with a coded outcome, Ongoing is the leading category at 37.5%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on S-Adenosylmethionine/Silybin.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial